These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
67. [NTRK Fusions: A new way of treatment for gastro-intestinal tumor?]. Ouali K; Pellat A; Cohen R; Svrcek M; Penault-Llorca F; André T Bull Cancer; 2020 Apr; 107(4):447-457. PubMed ID: 32067719 [TBL] [Abstract][Full Text] [Related]
68. Zurletrectinib is a next-generation TRK inhibitor with strong intracranial activity against NTRK fusion-positive tumours with on-target resistance to first-generation agents. Roa P; Foglizzo V; Harada G; Repetto M; Kulick A; de Stanchina E; de Marchena M; Auwardt S; Sayed Ahmed S; Bremer NV; Yang SR; Feng Y; Zhou C; Kong N; Liang R; Xu H; Zhang B; Bardelli A; Toska E; Ventura A; Drilon A; Cocco E Br J Cancer; 2024 Aug; 131(3):601-610. PubMed ID: 38902532 [TBL] [Abstract][Full Text] [Related]
69. Tropomyosin Receptor Kinase Inhibitors for the Treatment of TRK Fusion Cancer. Laetsch TW; Hong DS Clin Cancer Res; 2021 Sep; 27(18):4974-4982. PubMed ID: 33893159 [TBL] [Abstract][Full Text] [Related]
70. Pan-Trk Immunohistochemistry Is an Efficient and Reliable Screen for the Detection of NTRK Fusions. Hechtman JF; Benayed R; Hyman DM; Drilon A; Zehir A; Frosina D; Arcila ME; Dogan S; Klimstra DS; Ladanyi M; Jungbluth AA Am J Surg Pathol; 2017 Nov; 41(11):1547-1551. PubMed ID: 28719467 [TBL] [Abstract][Full Text] [Related]
71. Unclassified mesenchymal sarcoma with NTRK1-KHDRBS1 gene fusion: a case report of long-term tumor-free survival with crizotinib treatment. Chen W; Wang H; Jiang D; Luan L; Zhou Y; Hou Y World J Surg Oncol; 2021 Apr; 19(1):136. PubMed ID: 33941195 [TBL] [Abstract][Full Text] [Related]
72. Testing algorithm for identification of patients with TRK fusion cancer. Penault-Llorca F; Rudzinski ER; Sepulveda AR J Clin Pathol; 2019 Jul; 72(7):460-467. PubMed ID: 31072837 [TBL] [Abstract][Full Text] [Related]
73. NTRK-rearranged spindle cell sarcoma of the uterine cervix with a novel NUMA1::NTRK1 fusion. Szalai L; Vereczkey I; Szemes M; Rókusz A; Csernák E; Tóth E; Melegh Z Virchows Arch; 2024 Mar; 484(3):527-531. PubMed ID: 38151535 [TBL] [Abstract][Full Text] [Related]
74. Recurrent BRAF Gene Fusions in a Subset of Pediatric Spindle Cell Sarcomas: Expanding the Genetic Spectrum of Tumors With Overlapping Features With Infantile Fibrosarcoma. Kao YC; Fletcher CDM; Alaggio R; Wexler L; Zhang L; Sung YS; Orhan D; Chang WC; Swanson D; Dickson BC; Antonescu CR Am J Surg Pathol; 2018 Jan; 42(1):28-38. PubMed ID: 28877062 [TBL] [Abstract][Full Text] [Related]
75. Molecular Characteristics of Repotrectinib That Enable Potent Inhibition of TRK Fusion Proteins and Resistant Mutations. Murray BW; Rogers E; Zhai D; Deng W; Chen X; Sprengeler PA; Zhang X; Graber A; Reich SH; Stopatschinskaja S; Solomon B; Besse B; Drilon A Mol Cancer Ther; 2021 Dec; 20(12):2446-2456. PubMed ID: 34625502 [No Abstract] [Full Text] [Related]
76. An Oncogenic NTRK Fusion in a Patient with Soft-Tissue Sarcoma with Response to the Tropomyosin-Related Kinase Inhibitor LOXO-101. Doebele RC; Davis LE; Vaishnavi A; Le AT; Estrada-Bernal A; Keysar S; Jimeno A; Varella-Garcia M; Aisner DL; Li Y; Stephens PJ; Morosini D; Tuch BB; Fernandes M; Nanda N; Low JA Cancer Discov; 2015 Oct; 5(10):1049-57. PubMed ID: 26216294 [TBL] [Abstract][Full Text] [Related]
77. Efficacy and safety of NTRK inhibitors in patients with NTRK fusion-positive lung and thyroid cancers. Hong DS; Drilon A; Wirth LJ Clin Adv Hematol Oncol; 2024; 22 Suppl 5(6):1-20. PubMed ID: 38953725 [TBL] [Abstract][Full Text] [Related]
78. Belgian expert consensus for tumor-agnostic treatment of NTRK gene fusion-driven solid tumors with larotrectinib. Awada A; Berghmans T; Clement PM; Cuppens K; De Wilde B; Machiels JP; Pauwels P; Peeters M; Rottey S; Van Cutsem E Crit Rev Oncol Hematol; 2022 Jan; 169():103564. PubMed ID: 34861380 [TBL] [Abstract][Full Text] [Related]